Furosemide + amiloride

Generic Medicine Info
Severe Na and water depletion, hypersensitivity to sulphonamides and furosemide, hypokaelemia, hyponatremia, precomatose states associated with liver cirrhosis, Addison's disease, K sparing agents, K supplements, impaired renal function, hyperkalaemia, anuria, hypersensitivity.
Special Precautions
Hepatic or renal impairment, pregnancy, lactation, gout, diabetes, impaired micturition and metabolic or resp acidosis.
Adverse Reactions
nausea, diarrhoea, blurred vision, dizziness, headache, photosensitivity, hypotension, bone marrow depression (rare), hepatic dysfunction, hyperglycaemia, glycosuria, ototoxicity, hyponatraemia, idiosyncratic hypersensitivity, dry mouth, fatigue, muscle cramps, nausea, impotence, raised blood levels of glucose, urates, lipids,calcium, reduced levels of K and magnesium, raised CPK levels.
Potentially Fatal: Fluid and electrolyte imbalance, hypersens.
Drug Interactions
Phenytoin and indometacin may reduce effects of furosemide. May provoke severe hypotensive response with ACE inhibitors. NSAIDs inhibit diuretic and antihypertensive effects. Effects of antihypertensive drugs are enhanced. Increased incidence of premature beats with cardiac glycosides. Action antagonized by corticosteroids. Diuretic induced vol depletion can potentiate aminoglycoside nephrotoxicity. Impairs action of oral hypoglycaemic agents. Enhances digitalis toxicity due to hypokalaemia. vol depletion enhances lithium toxicity; conversely sudden stopping of diuretic may result in subtherapeutic levels of circulating lithium. Prolonged paralysis with tubocurarine due to hypokalaemia. NSAIDs antagonize hypotensive action. Suppresses action of oral anticoagulants due to reduced prothrombin activity. Increased risk of hypokalaemia when corticosteroids given concurrently.
CIMS Class
ATC Classification
C03CA01 - furosemide ; Belongs to the class of high-ceiling sulfonamide diuretics.
C03DB01 - amiloride ; Belongs to the class of other potassium-sparing agents. Used as diuretics.
Disclaimer: This information is independently developed by CIMS based on furosemide + amiloride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in